Global Point of Care
BACK
  • United States
Home > Products

ID NOW™ COVID-19

Molecular. In minutes. On the front line.

ID NOW™ is a leading molecular point-of-care platform in the United States, trusted by hospitals, physician offices, and urgent care clinics nationwide.

The ID NOW™ COVID-19 assay is now available for use on the ID NOW platform under U.S. Food and Drug Administration Emergency Use Authorization (EUA). The ID NOW™ COVID-19 rapid test delivers high-quality molecular positive results in as little as 5 minutes, targeting the coronavirus (COVID-19) RdRp Gene.

Timely results enable healthcare professionals to make appropriate and more efficient treatment and infection control decisions. EUA supports flexible near patient testing environments.

Only available in the US.

Benefits
  • Positive results may be detected in as little as 5 minutes 
  • Negative results in 13 minutes
  • Molecular technology targeting COVID-19 RdRp gene
  • Designed for near patient testing in a variety of healthcare environments1
  • Room temperature storage
  • Direct sample types include: Nasal, Throat, and Nasopharyngeal swabs
  • Facilitates effective patient management
Abbott Solution

Listen to a timely educational webinar on the CARES Act, information gathering and test reporting for COVID-19 testing sites.

Watch Now
Webinar
One Abbott solution for patient testing, result capture and data reporting

A simple, reliable and secure connectivity and reporting solution, offering ID NOW COVID-19 test reporting within 24 hours for decentralized environments to help you manage data for CARES Act requirements without infrastructure burden.

One Abbott Solution
Helpful Documents
  • Small footprint enables ease of use at point of care
  • Actionable results in 13 minutes or less
  • Direct sample types include: Nasal, Throat, and Nasopharyngeal swabs
  • Simple operation via visual touchscreen
  • Dimensions - 8.15” W x 5.71” H x 7.64” D (207 mm W x 145 mm H x 194 mm D)
  • Assay kit contains all necessary components for testing to include: 24 tests, swabs for sample collection, pipettes, positive and negative controls
ID NOW™ System
 Code
ID NOW™ Instrument
 NAT-000 (Global)
ID NOW™ COVID-19 24 Test Kit 190-000 (US)
ID NOW™ COVID-19 Control Kit (12 pos, 12 neg) 190-080 (US)
ID NOW™ Barcode Scanner OPR2001ZWU1-201 (Global)
Abbott Barcode Scanner L22XWU1200 (US)
Universal Printer 55115 (Global)
  IDNOWPRINT, formerly alereiprinter (US)

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an
emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only
for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the
duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic
tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
authorization is terminated or revoked sooner.

1. Please see ID NOW Instrument User manual for additional operating environment requirements.

Test Availability Updates

For additional information on NAVICA™ Mobile App and BinaxNOW™ COVID-19 Ag Card test availability.

Sign Up Now

Need Technical Support?

Click here to get in touch with our technical support team.

   

False
accessibility

   

YesNo
accessibility

   

YesNo
accessibility

   

YesNo
More Info